Purpose: The Pediatric Lupus Research Grant is intended to provide pilot funding for a new project or research idea focused on pediatric systemic lupus erythematosus (SLE). This grant provides support to investigators to initiate new research ideas and projects and is intended to complement rather than compete with traditional sources of funding.
Funding Opportunity
Applications to the Pediatric Lupus Research Grant will be adjudicated through a peer reviewed process. There are funds available to award one project for a term of one year at up to $45,000.00 USD each. Grants are nonrenewable and cannot be carried forward.
The single strongest predictor is a proposal that directly advances lupus research, including:
Systemic lupus erythematosus (SLE) mechanisms
Lupus nephritis
Neuropsychiatric lupus
Pediatric/juvenile lupus
Autoantibodies, B-cell & T-cell dysregulation
Innate immune activation, interferon signatures
Biomarker discovery (blood, urine, imaging)
Clinical trials, outcomes research
Lupus flares, disease prediction
Fatigue, quality of life, adherence
❗ Generic autoimmunity proposals score poorly unless strongly tied to lupus biology or lupus patients.
Different LFA funding lines have different expectations:
🔹 Gina M. Finzi Memorial Fellowship
For trainees and early-career researchers
Emphasizes mentoring + scientific potential
Requires feasible, compact projects (1 year)
🔹 LFA Research Grants (Pilot → Mid-Scale)
For early- to mid-career PIs
Requires strong preliminary data
Focus on novel lupus mechanisms or biomarkers
🔹 LFA-Funded Clinical / Biomarker Consortia
Support translational or clinical-type studies
Require strong clinical access and collaboration
🔹 LFA Special Calls (e.g., pediatric lupus, LN biomarkers, disparities)
Require tight alignment with the specific topic
Predictor: Match your career stage, research maturity, and topic precisely to the mechanism.
LFA prioritizes research that can produce meaningful change in lupus care:
New biomarkers for early detection or flare prediction
Therapeutic targets (B cells, T cells, interferon pathways, complement)
Novel therapeutics or mechanisms of drug resistance
Precision medicine approaches
Multi-omics for lupus heterogeneity
Real-world impact on lupus outcomes, disparities, fatigue
Predictor: Clearly articulate why this will matter clinically for lupus patients.
Even for early-career awards, successful applications typically provide:
Proof-of-concept experiments
Feasibility reports (assay working, cell lines, animal models)
Pilot data from lupus patients
Early biomarker signals
Predictor: Strong preliminary data greatly increases reviewer confidence.
LFA highly values clinically relevant lupus biology:
SLE patient samples (blood, urine, tissue)
Lupus nephritis kidney tissue
Reliable lupus mouse models (MRL/lpr, NZB/NZW F1)
Single-cell or bulk transcriptomics from lupus cohorts
Predictive computational models validated in real data
Predictor: Access to human lupus samples or well-validated models is crucial.
Most LFA grants are short-term (1–2 years), so strong proposals include:
2–3 focused Aims
Defined readouts (cytokines, autoantibodies, imaging, biomarkers)
Milestones with go/no-go criteria
Realistic timeline for a small award
Path to next-step NIH or foundation funding
Predictor: Tightly scoped, feasible Aims score highest.
For trainees and early-stage investigators, success correlates heavily with:
A mentor deeply experienced in lupus research
Strong training plan
Regular meetings and oversight
Access to lupus clinics, cohorts, biobanks, animal models
A track record of mentor-funded trainees
Predictor: The mentor’s quality is one of the top scoring criteria for trainee mechanisms.
LFA is especially focused on:
Improving lupus diagnosis and flare prediction
Reducing disparities in diagnosis, treatment, and outcomes
Pediatric lupus (often severe and under-studied)
Lupus nephritis (biomarkers, treatment optimization)
Fatigue and quality of life
Treatment optimization and clinical effectiveness
Predictor: Direct alignment with these priority areas significantly strengthens an application.
Top-scoring LFA proposals are:
Very clearly written
Well-organized
Supported by compelling preliminary data figures
Explicit about potential pitfalls & alternatives
Strong in biostatistics and reproducibility plans
Easy for both clinical and basic reviewers to understand
Predictor: Strong writing substantially increases reviewer enthusiasm.
LFA favors projects that can lead to:
NIH R21/R01/K-level applications
Clinical trial development
Biomarker qualification
Translational pipelines
Future patient-impact programs
Predictor: Show how the LFA grant propels your next major step.
| Predictor | Why It Matters |
|---|---|
| Lupus/SLE-specific focus | Core mission requirement |
| Mechanism alignment | Ensures appropriate expectations |
| Innovation + impact | Major scoring factor |
| Preliminary data | Shows feasibility |
| Human samples/models | Strengthens relevance |
| Focused Specific Aims | Fits 1–2 year timelines |
| Strong mentorship | Essential for early-career awards |
| Alignment with LFA priorities | Improves competitiveness |
| Strong writing & rigor | Improves reviewer scoring |
| Future funding pathway | Fits LFA’s “catalytic” philosophy |
Applicants and co-applicants must:
Hold an MD or PhD (or equivalent) from an accredited institution in the U.S. or Canada
Be a citizen or legal resident of the U.S. or Canada at the time of application. Collaborators may be from other countries, however no funds from the Lupus Foundation of America may be transferred outside of the U.S. or Canada.
Hold an academic appointment at an U.S. or Canadian university, teaching hospital, or similarly accredited institution (i.e., institution eligible for NIH funding or tri-council funding)
Principal Investigators are permitted to submit up to a maximum of one application per competition
Eligible Countries:
Sponsor Institute/Organizations: Lupus Foundation of America
Sponsor Type: Corporate/Non-Profit
Address: 2121 K Street NW, Suite 200 Washington, DC 20037
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Jan 16, 2026
Jan 16, 2026
$45,000
Affiliation: Lupus Foundation of America
Address: 2121 K Street NW, Suite 200 Washington, DC 20037
Website URL: https://www.lupus.org/research/apply-for-funding
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.